Back HIV/AIDS

HIV / AIDS

Less Frequent CD4 and Viral Load Monitoring Safe for People Doing Well on ART

The frequency of routine monitoring for people treated with antiretrovirals who have viral suppression can be safely reduced from every 3 months to every 6 months, investigators from Europe and the U.S. reported in the June 1 edition of the Journal of Acquired Immune Deficiency Syndromes. However, people followed-up every 9 to 12 months were more likely to experience virological failure and also had lower CD4 cell increases compared to people monitored every 3 months.

alt

June 27 Is National HIV Testing Day

June 27 is National HIV Testing Day (#NHTD), an opportunity to promote HIV screening and awareness of its importance as a gateway to the continuum of care. According to the Centers for Disease Control and Prevention (CDC), 1 out of 8 of the estimated 1.2 million people living with HIV do not know they are infected, putting their long-term health at risk.

alt

Big Increase in Proportion of HIV+ People with Viral Suppression in US

The proportion of people living with HIV receiving care in the U.S. who accessed antiretroviral therapy (ART) and achieved viral suppression increased substantially between 2009 and 2013, according to research published in the May 20 online edition of AIDS.

alt

ASM Microbe 2016: PrEP Use Is Rising Fast in U.S., But Large Racial Disparities Remain

More than 49,000 people in the U.S. have filled prescriptions for Truvada for pre-exposure prophylaxis (PrEP) at retail pharmacies, according to the results of a survey by Gilead Sciences presented this week at the ASM Microbe conference in Boston. Among PrEP users with available data, most were white gay men; black people used PrEP much less often, despite having the highest rates of HIV infection.

alt

New HIV Infections Decline by 60% Among Children in Most Affected African Countries

HIV incidence has fallen dramatically for children in the African countries with the highest burdens of the disease, more pregnant women are receiving prophylactic antiretrovirals to prevent transmission, and half of infected children are now on antiretroviral treatment, according to a new UNAIDS report release this month to coincide with the United Nations General Assembly High-Level Meeting on Ending AIDS.

alt

ASM Microbe 2016: PRO-140 Antibody Injections Maintain Viral Suppression Off ART

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.

alt

Tenofovir/Emtricitabine Vaginal Ring Protects Monkeys Against HIV-Like Virus

A vaginal ring that releases tenofovir and emtricitabine -- the antiretroviral drugs in the Truvada PrEP pill -- maintained protective drug levels over 4 months, and all macaque monkeys that received the ring were protected from infection with an engineered HIV-like virus, researchers reported in the June 8 edition of PLoS ONE. A human study of a different type of tenofovir ring showed that it maintained protective drug levels in genital fluid and blood over 14 days.

alt